Genelabs Technologies, Inc. announced today that, after its receipt of $12.5 million in up-front payments under its recently announced agreement with Novartis, Genelabs expects its June 30, 2006 cash and cash equivalents to be approximately $15 million. The mid-year cash level anticipated by the company accounts for costs related to closing the transaction and anticipated second quarter operating expenses. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-09-2006/0004377619&EDATE=)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
NHS England Picks Up Glucose Monitors for Type 1 Diabetes Patients
The devices are now available on prescription for all patients that qualify through NHS’ clinical guidelines.
FDA Expands Approval of Bristol-Myers Squibb’s Empliciti
EPd is the first triplet combination approved based on a randomized clinical trial using pomalidomide and dexamethasone as comparators.
